JP Morgan Chase’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.41M Sell
5,000
-13,000
-72% -$6.72M ﹤0.01% 4118
2026
Q2
$9.8M Sell
18,000
-62,500
-78% -$35.2M ﹤0.01% 2820
2026
Q1
$47.4M Buy
80,500
+80,100
+20,025% +$39.9M ﹤0.01% 1435
2025
Q4
$195K Sell
400
-4,500
-92% -$2.1M ﹤0.01% 5559
2025
Q3
$2.05M Sell
4,900
-8,100
-62% -$2.72M ﹤0.01% 4062
2025
Q2
$3.74M Hold
13,000
– – ﹤0.01% 3417
2025
Q1
$4.01M Buy
13,000
+11,000
+550% +$3.77M ﹤0.01% 3349
2024
Q4
$706K Buy
+2,000
New +$735K ﹤0.01% 4854
2024
Q3
– Sell
-20,000
Closed -$6.37M – 7696
2024
Q2
$6.37M Hold
20,000
– – ﹤0.01% 2843
2024
Q1
$4.59M Buy
+20,000
New +$4.51M ﹤0.01% 3175
2023
Q2
– Sell
-19,200
Closed -$4.3M – 7355
2023
Q1
$4.3M Buy
+19,200
New +$4.73M ﹤0.01% 2952
2019
Q2
– Sell
-131,100
Closed -$15.4M – 6028
2019
Q1
$15.4M Buy
+131,100
New +$15.3M ﹤0.01% 1730

Other funds holding UTHR

JP Morgan Chase's UTHR Position: Q3 2026 in Review

JP Morgan Chase reduced its United Therapeutics (UTHR) stake by 28% in Q3 2026, selling an estimated $40.5M and leaving 197,107 shares worth $95.9M. The position accounts for 0.01% of the portfolio, ranked #1069.

JP Morgan Chase first reported a position in UTHR in Q2 2013 and has held it in 54 quarters since. The position peaked at $172M in Q1 2026. 848 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • JP Morgan Chase held 197,107 shares of United Therapeutics worth $95.9M as of Q3 2026.
  • JP Morgan Chase sold 78,251 United Therapeutics shares in Q3 2026, an estimated $40.5M.
  • United Therapeutics made up 0.01% of JP Morgan Chase's portfolio in Q3 2026, its #1069 holding.
  • JP Morgan Chase first reported a position in United Therapeutics in Q2 2013 and has held it in 54 quarters since.
  • JP Morgan Chase's United Therapeutics position peaked at $172M in Q1 2026.
  • 848 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.